70 related articles for article (PubMed ID: 9137529)
1. Combination chemotherapy involving orally administered etoposide and JM-216 in murine tumor models.
Rose WC
Cancer Chemother Pharmacol; 1997; 40(1):51-6. PubMed ID: 9137529
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
Elliott WL; Roberts BJ; Howard CT; Leopold WR
Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
[TBL] [Abstract][Full Text] [Related]
3. Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies.
Rose WC
J Natl Cancer Inst Monogr; 1993; (15):47-53. PubMed ID: 7912529
[TBL] [Abstract][Full Text] [Related]
4. Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta.
Borden EC; Sidky YA; Hatcher JF; Bryan GT
Cancer Res; 1988 May; 48(9):2329-34. PubMed ID: 3356000
[TBL] [Abstract][Full Text] [Related]
5. Preclinical antitumor activity of orally administered platinum (IV) complexes.
Rose WC; Crosswell AR; Schurig JE; Casazza AM
Cancer Chemother Pharmacol; 1993; 32(3):197-203. PubMed ID: 8500224
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days.
DeMario MD; Ratain MJ; Vogelzang NJ; Mani S; Vokes EE; Fleming GF; Melton K; Johnson S; Benner S; Lebwohl D
Cancer Chemother Pharmacol; 1999; 43(5):385-8. PubMed ID: 10100593
[TBL] [Abstract][Full Text] [Related]
7. [Combination therapy of a new platinum complex, DWA2114R with various antitumor agents against mouse tumors in vivo].
Akamatsu K; Endo K; Tsunenari T; Matsumoto T; Kaiho S; Morikawa K; Koizumi M; Mitsui H; Koizumi K
Gan To Kagaku Ryoho; 1992 Feb; 19(2):229-35. PubMed ID: 1736835
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.
O'Dwyer PJ; Moyer JD; Suffness M; Harrison SD; Cysyk R; Hamilton TC; Plowman J
Cancer Res; 1994 Feb; 54(3):724-9. PubMed ID: 8306334
[TBL] [Abstract][Full Text] [Related]
9. Combination vincristine and VP-16-213: evaluation of drug sequence.
Jackson DV; Long TR; Rice DG; Morgan TM
Cancer Biochem Biophys; 1986 Oct; 8(4):265-75. PubMed ID: 3802048
[TBL] [Abstract][Full Text] [Related]
10. A new orally active antitumor 1R,2R-cyclohexanediamine-platinum(IV) complex: trans-(n-valerato)chloro(1R,2R-cyclohexanediamine) (oxalato)platinum(IV).
Kizu R; Nakanishi T; Hayakawa K; Matsuzawa A; Eriguchi M; Takeda Y; Akiyama N; Tashiro T; Kidani Y
Cancer Chemother Pharmacol; 1999; 43(2):97-105. PubMed ID: 9923814
[TBL] [Abstract][Full Text] [Related]
11. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
[TBL] [Abstract][Full Text] [Related]
12. Combined oral administration of etoposide and arabinofuranosylcytosine-5'-stearylphosphate enhances the antitumor effect against P388 ascites tumors.
Higashigawa M; Cao DC; Matsui K; Yamada S; Kakitou H; Kagawa Y; Inamochi H; Ido M; Sakurai M
Cancer Chemother Pharmacol; 1994; 33(4):281-5. PubMed ID: 8281619
[TBL] [Abstract][Full Text] [Related]
13. Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models.
Winkelhake JL; Stampfl S; Zimmerman RJ
Cancer Res; 1987 Aug; 47(15):3948-53. PubMed ID: 3496953
[TBL] [Abstract][Full Text] [Related]
14. Synergy of the combination of nedaplatin with etoposide in murine and human lung carcinoma.
Uchida N; Kasai H; Takeda Y; Maekawa R; Sugita K; Yoshioka T
Anticancer Res; 1998; 18(1A):247-52. PubMed ID: 9568085
[TBL] [Abstract][Full Text] [Related]
15. Use of etoposide in combination with cyclosporin for purging multidrug-resistant leukemic cells from bone marrow in a mouse model.
Kühl JS; Sikic BI; Blume KG; Chao NJ
Exp Hematol; 1992 Oct; 20(9):1048-54. PubMed ID: 1468539
[TBL] [Abstract][Full Text] [Related]
16. L-histidinol: preclinical therapeutic studies in combination with antitumor agents and pharmacokinetic studies in mice.
Zaharko D; Plowman J; Waud W; Dykes D; Malspeis L
Cancer Res; 1992 Jul; 52(13):3604-9. PubMed ID: 1617631
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effects of pirarubicin and epirubicin in combination with doxifluridine and cisplatin against mouse P388 leukemia.
Agata N; Mase T; Izumi H; Hirano S; Iguchi H; Tone H; Takeuchi T
Cancer Biochem Biophys; 1995 Nov; 15(2):95-101. PubMed ID: 8590441
[TBL] [Abstract][Full Text] [Related]
18. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.
McKeage MJ; Kelland LR; Boxall FE; Valenti MR; Jones M; Goddard PM; Gwynne J; Harrap KR
Cancer Res; 1994 Aug; 54(15):4118-22. PubMed ID: 8033145
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of paclitaxel with oral etoposide in advanced solid tumors.
Perez EA; Coe T; Turrell C; Lau D; Campbell D; Gandara D
Cancer J Sci Am; 1996; 2(5):286-90. PubMed ID: 9166546
[TBL] [Abstract][Full Text] [Related]
20. cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice.
Schabel FM; Trader MW; Laster WR; Corbett TH; Griswold DP
Cancer Treat Rep; 1979; 63(9-10):1459-73. PubMed ID: 291480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
